Familial Ovarian Cancer Clusters with Other Cancers by Zheng, Guoqiao et al.
1SCiEnTiFiC RepORtS |  (2018) 8:11561  | DOI:10.1038/s41598-018-29888-4
www.nature.com/scientificreports
Familial Ovarian Cancer 
Clusters with Other Cancers
Guoqiao Zheng  1,2, Hongyao Yu1,2, Anna Kanerva3,4, Asta Försti1,5, Kristina Sundquist5,6,7 & 
Kari Hemminki1,5
Familial risk of ovarian cancer is well-established but whether ovarian cancer clusters with other 
cancers and the clusters differ by histology remains uncertain. Using data from the Swedish Family-
Cancer Database, we explored familial associations of ovarian cancer with other cancers with a novel 
approach; relative risk for (histology-specific) ovarian cancer was estimated in families with patients 
affected by other cancers, and conversely, risks for other cancers in families with (histology-specific) 
ovarian cancer patients. Eight discordant cancers were associated with ovarian cancer risk, of which 
family history of breast cancer showed a dose-response (P-trend <0.0001). Conversely, risks of eight 
types of cancer increased in families with ovarian cancer patients, and dose-responses were shown for 
risks of liver (P-trend = 0.0083) and breast cancers (P-trend <0.0001) and cancer of unknown primary 
(P-trend = 0.0157). Some cancers were only associated with histology-specific ovarian cancers, e.g. 
endometrial cancer was only associated with endometrioid type but with highest significance. Novel 
associations with virus-linked cancers of the nose and male and female genitals were found. The results 
suggest that ovarian cancer shares susceptibility with a number of other cancers. This might alert 
genetic counselors and challenge approaches for gene and gene-environment identification.
Ovarian cancer is a heterogeneous disease commonly classified into epithelial and non-epithelial types. 
Histologically, epithelial ovarian cancer includes high-grade serous, low-grade serous, endometrioid, clear cell 
and mucinous carcinoma1. Non-epithelial ovarian cancer, which accounts for less than 10% of all ovarian cancer 
cases2, comprises many tumor types such as granulosa cell and germinal malignancies, teratomas, and dysger-
minomas; we refer to these as non-epithelial tumors. Distinctive susceptibility to protective and risk factors such 
as oral contraceptives, endometriosis, and smoking has been observed for different histological types of ovarian 
cancer3. Furthermore, histology-specific ovarian cancers present different prognoses. For example,patient with 
high-grade serous ovarian carcinoma always has poor prognosis compared to other types because most patients 
(∼80%) present with advanced stage at diagnosis1.
It is well-known that family history of ovarian cancer is associated with increased ovarian cancer risk and 
the relative risk is estimated to be 2.0 to 4.0 when having a first-degree relative affected by ovarian cancer4–8. The 
most common genes predisposing to ovarian cancer are BRCA1/2, which are associated with high-grade serous 
histology9,10. Mutations in mismatch repair (MMR) genes, which are responsible for the hereditary nonpolyposis 
colorectal cancer (HNPCC) syndrome, also contribute to the familial ovarian cancer with a tendency towards 
endometriod and clear cell histology11,12. Some other moderate and low penetrant genes, including BRIP1, 
RAD51C and RAD51D may also contribute to ovarian cancer risk13. All high- and moderate risk genes predispos-
ing to ovarian cancer also increase risks for other, i.e. discordant, cancers. For instance, BRCA1/2 mutations pre-
dispose to breast, prostate, pancreatic and some other cancers14; MMR gene mutations predispose to colorectal, 
endometrial and stomach cancers15; and rare PALB2 mutations predispose to breast and prostate cancer16,17. At 
the population level, discordant associations of ovarian cancer have been observed with breast, endometrial and 
prostate cancers18–20, and also with some other cancers with lower statistical significance21,22. There are very few 
studies concerning associations of histological specific ovarian cancer with other cancers and our own work dates 
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a decade back when the Swedish Family-Cancer Database was far from its present size18. Our present study covers 
8,850 patients with histological information until the end of 2015, doubling the power of detection compared to 
the previous study, which included 4,082 such cases18.
The aim of our present study was to explore the familial associations of histology-specific ovarian cancer with 
other discordant cancers using multiple independent analyses for reliable results. The patient population includes 
46,227 ovarian cancer patients and 10,639 other cancer patients who had a family history of ovarian cancer in 
first degree relatives. Our results should be relevant for genetic counseling, precise treatment and health care for 
patients with ovarian cancer and may provide clues about shared genetic and/or environmental risk factors.
Results
A total of 46,227 ovarian cancer patients were found in the database, of which 11,301 were diagnosed in the 
offspring generation at the median age of 63-years-old (Table 1). There were 8,850 ovarian cancer patients in the 
offspring generation diagnosed since 1993 when Systemized Nomenclature of Medicine (SNOMED) codes were 
applied, and 11.9% of them were non-epithelial ovarian cancers. In the offspring generation, there were 4526 
(40.0%) patients who had one first-degree relative affected by any discordant cancer and 2395 (21.2%) patients 
had at least two first-degree relatives affected by any discordant cancer. For ovarian cancer alone, there were 467 
(4.3%) patients who had one first-degree relative affected by ovarian cancer and 20 (0.2%) patients that had two 
affected first-degree relatives.
The principles of the bi-directional analyses are shown in Fig. 1. On the left side, RR is calculated for ovar-
ian cancer (OC); person-years at risk are calculated for all persons in the offspring generation; probands are 
all first-degree relatives with cancer X. In the reverse analysis, (on the right side) RR is calculated for cancer X 
when first-degree relatives have ovarian cancer. For parent-offspring generations, the pairs of individuals are 
No. of females followed 4,216,676
No. of ovarian cancer patients 11,301
No. of ovarian cancer patients (1993–2015) 8850
Median age at diagnosis of ovarian cancer 63 years old
No. of ovarian cancer patients with family 
history of ovarian cancer
In one first-degree relative 467 (4.3%)
In at least two first-degree relatives 20 (0.2%)
No. of ovarian cancer patients with family 
history of discordant cancers
In one first-degree relative 4526 (40.0%)
In at least two first-degree relatives 2395 (21.2%)
Histological types (1993–2015)
Undifferentiated 193 (2.2%)






300 of them 
were thecoma
Others 1219 (13.8%)
Table 1. Characteristics of ovarian cancer patients in offspring generation (1958–2015). Others include 
histological types of other ovarian cancers such as papillary ovarian cancer, as well as unspecified ovarian 
cancers.
Figure 1. Flowchart of calculating the RRs for ovarian cancer and cancer X in a two-way analysis. On the 
left side, RR was calculated for ovarian cancer when family history was cancer X; person-years at risk were 
calculated for all offspring; probands were all first-degree relatives. On the right side, RR was calculated for 
cancer X when family history was ovarian cancer. OC: ovarian cancer.
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independent between the two analyses but for siblings the pairs of individuals are the same and thus not com-
pletely independent.
Table 2 shows the invasive ovarian cancer risk when first-degree relatives were diagnosed with ovarian cancer 
or other cancers and cancer sites with significant results are shown in the forest plot (Fig. 2). The cancer sites with 
less than 30 cases having affected first-degree relative and insignificant results are not displayed in Table 2 nor in 
the following Table. The relative risk of ovarian cancer was 2.42 in families with one ovarian cancer patient and it 
reached 11.36 with two affected first-degree relatives, both of which were significant at a 0.001 level. For discord-
ant cancer, eight cancers showed  significant results in the associations with the risk of ovarian cancer. Family his-
tory of breast cancer showed a dose-response on ovarian cancer risk (P-trend test <0.001). RR was 1.20 when one 
first-degree relative was diagnosed with breast cancer (P < 0.001) and RR was 1.47 when two first-degree relatives 
were affected (P < 0.01). Ovarian cancer risk increased in families with one first-degree relative diagnosed with 
colorectal (1.06), liver (1.20, P < 0.01), pancreatic (1.14) and endometrial (RR 1.27, P < 0.001) cancers, melanoma 
(1.12) and cancer of unknown primary (CUP, 1.25 P < 0.001). For liver cancer subtypes (N = 277), we observed 
increased risk of ovarian cancer in families of patients with gallbladder cancer (N = 95, 34.3% of all liver cancer; 
RR = 1.27, 95%CI 1.03–1.55; see Supplementary Table S1). Risk of ovarian cancer was found to be elevated in 
families that had one patient diagnosed with any cancer (1.13), and RR was 1.29 when the families had at least 
two cancer patients. When only considering the family history of discordant cancers, we found the risk of ovarian 
cancer was still significantly increased. Statistical power to detect a significant association is shown in Table 2. 
This is calculated for two-sided confidence level of 95% and an RR of 1.20 for one first-degree relative affected by 
other cancer and an RR of 1.40 when at least two first-degree relatives were affected. In families of one affected 
Cancer site
Patients with 1 FDR Patients with ≥ 2 FDRs
P-trendN RR 95%CI
Power (%) 
RR = 1.2 N RR 95%CI
Power (%) 
RR = 1.4
Ovary 467 2.42 2.21–2.66 46.6 20 11.36 7.33–17.62 8.2 <0.0001
Upper aerodigestive tract 239 1.08 0.95–1.23 52.7 4 1.46 0.55–3.90 9.1 0.1887
Esophagus 70 0.94 0.74–1.19 22.8 0 — — — 0.6042
Stomach 349 1.08 0.97–1.2 56.4 3 0.57 0.18–1.76 10.5 0.2887
Small intestine 41 1.02 0.75–1.38 16.3 1 4.07 0.57–28.93 37.7 0.7269
Colorectum 1009 1.06 1.00–1.13 96.7 58 1.16 0.89–1.50 37.7 0.0377
Colon 659 1.04 0.96–1.13 88.3 28 1.33 0.92–1.92 22.0 0.141
Rectum 395 1.07 0.97–1.19 69.7 10 1.48 0.80–2.76 12.3 0.0974
Liver 277 1.20 1.06–1.35 48.9 4 1.64 0.62–4.38 8.6 0.0024
Pancreas 271 1.14 1.01–1.28 50.4 2 0.70 0.18–2.80 9.1 0.0595
Lung 655 1.05 0.97–1.14 89.6 27 1.04 0.71–1.52 26.3 0.2382
Breast 1243 1.20 1.14–1.28 99.2 88 1.47 1.20–1.82 43.8 <0.0001
Cervix 184 1.14 0.98–1.32 45.1 0 — — — 0.0862
Endometrium 317 1.27 1.14–1.42 54.4 4 1.40 0.53–3.73 9.0 <0.0001
Other female genitals 39 0.94 0.69–1.29 15.0 0 — — — 0.7144
Prostate 1320 1.02 0.96–1.08 99.6 121 1.14 0.95–1.36 56.2 0.2174
Testis 35 1.20 0.86–1.68 23.8 1 4.37 0.62–31.03 6.7 0.1904
Other male genitals 30 1.74 1.21–2.49 10.4 0 — — — 0.0056
Kidney 276 1.08 0.96–1.22 56.2 3 0.89 0.29–2.75 9.6 0.2458
Bladder 403 0.96 0.87–1.06 75.5 14 1.57 0.93–2.66 13.7 0.8195
Melanoma 339 1.12 1.00–1.25 78.4 8 1.02 0.51–2.04 16.1 0.0573
Skin 387 0.98 0.88–1.08 72.4 12 1.20 0.68–2.11 14.8 0.8309
Nervous system 279 1.08 0.96–1.22 68.4 2 0.49 0.12–1.97 11.3 0.2972
Thyroid gland 75 1.04 0.83–1.31 29.0 0 — — — 0.7147
Endocrine glands 148 0.97 0.83–1.14 45.5 1 0.72 0.10–5.10 8.2 0.6948
Connective tissue 61 1.06 0.83–1.37 21.9 0 — — — 0.6436
Non-Hodgkin lymphoma 296 1.08 0.96–1.21 63.6 5 1.27 0.53–3.05 10.5 0.1882
Hodgkin lymphoma 52 1.28 0.97–1.68 20.0 0 — — — 0.0887
Myeloma 141 1.07 0.90–1.26 33.6 0 — — — 0.4464
Leukemia 250 0.99 0.87–1.12 60.7 2 0.50 0.13–2.01 10.4 0.6704
CUP 396 1.25 1.13–1.38 62.4 4 1.08 0.40–2.87 10.0 <0.0001
All cancersa 4553 1.13 1.09–1.18 100.0 2589 1.29 1.23–1.36 100.0 <0.0001
All cancersb 4340 1.10 1.06–1.15 100.0 2315 1.20 1.14–1.27 100.0 <0.0001
Table 2. Invasive ovarian cancer risk when first-degree relatives were diagnosed with other cancers. FDR: first-
degree relative; CUP: cancer of unknown primary. Bolding, italic and underlining indicate that the 95% CI, 
99% CI and 99.9% CI did not overlap with 1.00 respectively. aall cancers include ovarian cancers and all other 
cancers. ball cancers include all other cancers except ovarian cancer.
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first-degree relative, an 80% power was reached only for  colorectal, lung, breast and prostate cancers. In families 
of more than one first-degree relative affected, no association reached a power of 80% at an RR of 1.4.
In the reverse comparison, the overall cancer risk in the offspring generation increased when having a family 
history of ovarian cancer (Table 3). All the significant cancer sites are displayed in Fig. 3. The estimated RR was 
1.12 (P < 0.001) in families of one first-degree relative affected by ovarian cancer and it was 1.49 (P < 0.001) 
when at least two were affected. Excluding ovarian cancer, the RRs for any other cancer were 1.09 (P < 0.001) 
and 1.31(P < 0.01), respectively. Five cancers (colorectal, liver, breast, endometrial cancers and CUP) were 
observed with significant results in the two-way comparison and family history of ovarian cancer showed 
dose-response effect on the risk of liver and breast cancers and CUP. Notably, when at least two first-degree 
relatives were diagnosed with ovarian cancer, the relative risk for Hodgkin lymphoma reached 4.11 (P < 0.01). 
However, that association was based on two families. Elevated risks were also observed for lung (1.10) and pros-
tate (1.06) cancer when one first-degree relative was affected by ovarian cancer. Risk of esophageal (0.76) cancer 
declined in families with one first-degree relative diagnosed with ovarian cancer. In families of one first-degree 
relative diagnosed with ovarian cancer, an 80% power (RR of 1.2) was reached by colorectal, lung, breast and 
prostate cancers and by melanoma. In families with more than one first-degree relative affected, no association 
reached a power of 80% (1.4).
In the search of the familial associations of histology-specific ovarian cancer with other cancers, some 
significant results were observed (Table 4; note that both of the two-way comparisons are shown). The sig-
nificant pairs (histology type-cancer site) in the two-way analysis were clear cell-pancreas (joint P < 0.0025), 
endometrioid-nose (joint P < 0.0025), endometrioid-breast (joint P < 0.0005), endometrioid- endometrium 
(joint P < 10−6), serous-breast (joint P < 10−6), serous-male genitals (joint P < 5 × 10−5), mucinous-gallbladder 
(joint P < 10−4; see Supplementary Table S2). For the above pair ‘endometrioid-endometrium’, 40 of 999 patients 
with endometrioid ovarian cancer were diagnosed within five months with endometrial cancer thus resulting in 
an RR of 9.49 (6.96–12.95) for endometrial cancer compared to the risk of first endometrial cancer. Conversely, 
164 patients were diagnosed with ovarian cancer among the 12,294 patients with endometrial cancer, and 76 of 
these were of endometrioid histology; more than half of these were diagnosed in the same month as those with 
endometrial cancer. The RR of endometrioid ovarian cancer after endometrial cancer was 20.30 (15.92–25.90, see 
Supplementary Table S3). For the pair endometrioid-nose, the available histology for cancer of nose included two 
squamous cell carcinomas and one adenocarcinomas. Of note, results for non-epithelial ovarian cancer were all 
based on a small number of cases.
Table 5 displays familial association of histology-specific ovarian cancer with any cancer. Undifferentiated, 
endometrioid, serous and mucinous ovarian cancers were significantly associated with any cancers, among which 
undifferentiated (joint P < 0.0025), endometrioid (joint P < 10−6) and serous (joint P < 5 × 10−5) types showed 
significant associations in the two-way comparison. After omitting ovarian cancer, results for endometrioid, 
serous and mucinous types were still significant in the associations with any discordant cancers and the associa-
tion of endometrioid carcinoma was significant in the two-way comparison (joint P < 10−5).
Discussion
With novel insight from our bi-directional statistical analyses, we found that ovarian cancer was associated with 
a group of discordant cancers, among which colorectal, breast, endometrial and liver cancers and CUP were 
significant in the two-way analysis. As the present study involves multiple comparisons we require, for credible 
familial associations, that more than a single analysis should be positive and RRs should show a ‘dose-response’ 
relationship, i.e. increase by the number of affected probands. For guidance, we use the joint P-values. Breast 
cancer showed four significant RRs, of which three were at a 0.1% confidence level; liver cancer and CUP showed 
three increased RRs, and colorectal and endometrial cancers showed two RRs. For endometrial cancer, the two 
RRs were both significant at 0.001 levels. Cancer in other male genitals showed a single significant RR at a 1% 
Figure 2. Ovarian cancer risk when only one or at least two first-degree relatives were diagnosed with other 
cancers. Only significant cancer sites are shown. CUP: cancer of unknown primary; aall cancers include ovarian 
cancers and all other cancers; ball cancers include all other cancers except ovarian cancer. FDR, first-degree 
relative.
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confidence level. The remaining cancers, including lung and prostate cancers, melanoma and Hodgkin lymphoma 
showed a single nominal significance. The association of ovarian cancer with breast cancer showed dose-response 
in the two-way comparison, and the ones with liver cancer and CUP showed dose-response in the one-way anal-
ysis. The ‘dose-response’ observation in RRs would support the findings and it is informative of the underlying 
genetic risk (penetrance) as many first-degree relatives diagnosed with the same cancers signal high penetrance.
Ovarian cancer showed the strongest association with breast cancer (joint P < 10−11) and it may be attributable 
to BRCA1/2 mutations as in the histological analysis breast cancer was associated with serous ovarian carcino-
mas, which have been reported to be related to BRCA1/2 mutations9,10. BRCA2 carriers have an increased risk of 
prostate cancer14,23, but one weak association was shown here. BAP1 mutations manifest eye and cutaneous mel-
anomas, ovarian cancers and several other cancers, and these may contribute to the associations with eye cancer 
(one of two was melanoma) and the weakly increased risk with cutaneous melanoma in Table 123,24. In our study, 
the association of ovarian cancer with colorectal cancer was weak and no significant associations were observed 
with endometrioid or clear cell ovarian cancers, which may not support the HNPCC link. By contrast, we found 
that endometrioid ovarian cancer was strongly associated with endometrial cancer in the two-way comparison, 
which could imply association with HNPCC syndrome related to MSH6 mutations in patients with the endome-
trioid and clear cell ovarian carcinomas25. Carriers with MSH6 germline mutations appear to have a high risk of 
endometrial cancer but low risk of colorectal cancer26.
Ovarian cancer is a heterogeneous disease and different histological types of ovarian cancer have distinctive 
risk factors, genetic characteristics and prognosis. Accordingly, our results of histology-based analysis suggest that 
Cancer site
Patients with 1 FDR Patients with ≥2 FDRs
P-trendN RR 95%CI
Power (%) 
RR = 1.2 N RR 95%CI
Power (%) 
RR = 1.4
Upper aerodigestive tract 220 1.02 0.89–1.17 49.3% 3 1.32 0.43–4.09 8.5 0.7011
Esophagus 52 0.76 0.58–1.00 20.5 1 1.29 0.18–9.16 6.6 0.0552
Stomach 134 1.11 0.94–1.32 31.3 3 2.29 0.74–7.10 7.4 0.1435
Small intestine 54 1.29 0.98–1.68 15.4 0 — — — 0.0793
Colorectum 884 1.07 1.00–1.15 95.1 6 0.70 0.31–1.56 13.4 0.0708
Colon 552 1.06 0.98–1.16 83.0 2 0.38 0.09–1.50 11.1 0.2651
Rectum 332 1.09 0.97–1.21 61.1 4 1.23 0.46–3.27 9.2 0.1264
Liver 167 1.20 1.03–1.40 35.2 4 2.66 1.00–7.10 7.6 0.0083
Pancreas 157 0.97 0.82–1.13 38.9 2 1.14 0.28–4.54 7.8 0.6918
Lung 634 1.10 1.01–1.19 85.4 5 0.80 0.33–1.92 11.4 0.0320
Breast 1981 1.24 1.19–1.30 99.9 30 2.13 1.49–3.05 19.5 <0.0001
Cervix 165 1.08 0.92–1.26 43.3 2 1.65 0.41–6.61 7.9 0.3036
Endometrium 304 1.22 1.09–1.36 53.8 2 0.86 0.21–3.44 8.5 0.0014
Uterusc 6 2.63 1.16–5.95 5.6 0 — — — 0.0439
Other female genitals 27 0.89 0.61–1.30 13.0 0 — — — 0.5488
Prostate 1727 1.05 1.00–1.10 99.9 29 1.40 0.97–2.01 20.2 0.0149
Testis 117 1.15 0.95–1.37 38.0 0 — — — 0.1551
Other male genitals 22 1.16 0.76–1.77 10.1 0 — — — 0.5002
Kidney 226 1.10 0.96–1.25 48.4 5 2.30 0.96–5.53 8.4 0.0905
Bladder 333 0.99 0.89–1.10 64.7 4 1.07 0.40–2.85 9.5 0.8401
Melanoma 628 1.07 0.99–1.16 89.7 7 1.29 0.62–2.71 12.1 0.0645
Skin 333 1.06 0.95–1.18 62.5 2 0.62 0.16–2.49 9.3 0.3549
Nervous system 380 1.04 0.94–1.15 77.9 3 0.89 0.29–2.77 10.6 0.4900
Thyroid gland 111 1.11 0.92–1.34 31.7 1 1.18 0.17–8.35 7.4 0.2767
Endocrine glands 193 1.01 0.88–1.16 48.0 2 1.13 0.28–4.51 8.4 0.8776
Connective tissue 70 1.01 0.79–1.28 23.0 0 — — — 0.4857
Non-Hodgkin lymphoma 327 1.11 0.99–1.24 63.2 3 0.99 0.32–3.08 9.4 0.0751
Hodgkin lymphoma 71 1.20 0.95–1.51 25.0 2 4.11 1.03–16.46 7.0 0.0732
Myeloma 107 1.09 0.90–1.32 26.5 0 — — — 0.3765
Leukemia 248 0.98 0.86–1.11 63.4 3 1.22 0.39–3.79 9.4 0.8095
CUP 227 1.14 1.00–1.30 45.8 6 2.81 1.26–6.26 8.3 0.0157
All cancersa 10492 1.12 1.10–1.14 100.0 147 1.49 1.27–1.75 68.7 <0.0001
All cancersb 10025 1.09 1.07–1.11 100.0 127 1.31 1.10–1.56 67.9 <0.0001
Table 3. Other cancer risk when first-degree relatives were diagnosed with invasive ovarian cancer. FDR: first-
degree relative; CUP: cancer of unknown primary. Bolding, italic and underlining indicate that the 95% CI, 
99% CI and 99.9% CI did not overlap with 1.00 respectively. aall cancers include ovarian cancers and all other 
cancers. ball cancers include all other cancers except ovarian cancer. ccancer of other parts of uterus, including 
chorionepithelioma.
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some specific histological types are associated only with specific cancers. Endometrial cancer was only associated 
with endometrioid ovarian cancer and this pair showed the most significance (RR > 2.00, joint P < 10−6) among 
all the histology-based associations. Most endometrioid ovarian cancers were synchronous with endometrial 
Figure 3. Other cancer risk when only one or at least two first-degree relatives were diagnosed with ovarian 
cancer. Only significant cancer sites are shown. CUP: cancer of unknown primary; aall cancers include ovarian 
cancers and all other cancers; ball cancers include all other cancers except ovarian cancer. FDR, first-degree 
relative; ccancer of other parts of uterus, including chorionepithelioma.
Histology Cancer site
Risk of ovarian cancer Risk of other cancer
N RR 95% CI
Power (%) 




Stomach 11 1.95 1.06–3.60 53.4 2 1.65 0.41–6.61 8.3
Liver 8 2.00 0.99–4.06 46.7 4 2.76 1.04–7.36 8.8
Pancreas 5 1.16 0.48–2.81 48.2 7 4.07 1.94–8.55 9.2
Lung 17 1.48 0.90–2.44 86.3 11 1.85 1.02–3.34 14.8
Hodgkin lymphoma 3 4.35 1.39–13.61 20.9 1 2.35 0.33–16.71 7.2
Clear cell
Pancreas 18 1.69 1.05–2.70 51.9 7 2.23 1.06–4.68 11.1
Testis 3 2.19 0.70–6.81 26.3 6 3.94 1.77–8.76 9.7
Endometrioid
Stomach 35 1.25 0.89–1.75 63.2 11 2.15 1.19–3.88 13.8
Nose 4 3.08 1.15–8.21 12.1 2 4.02 1.00–16.10 7.0
Lung 58 0.98 0.75–1.28 93.3 37 1.43 1.04–1.97 35.1
Breast 121 1.24 1.02–1.49 99.6 94 1.35 1.10–1.65 67.3
Endometrium 49 2.22 1.67–2.96 61.0 22 2.04 1.34–3.09 20.3
Other female genitals 6 1.65 0.74–3.69 18.7 4 3.08 1.16–8.22 8.5
Kidney 34 1.50 1.07–2.12 63.1 12 1.41 0.80–2.49 18.2
Connective tissue 8 1.54 0.77–3.09 26.7 6 2.53 1.13–5.63 10.8
Serous
Breast 515 1.27 1.15–1.39 100.0 373 1.24 1.12–1.38 58.9
Other male genitals 12 1.87 1.06–3.29 18.3 8 2.42 1.20–4.85 11.6
Thyroid gland 38 1.42 1.03–1.96 53.9 14 0.89 0.53–1.51 27.5
CUP 134 1.23 1.04–1.47 87.6 39 1.06 0.77–1.45 47.2
Mucinous
Upper aerodigestive tract 23 1.73 1.14–2.63 56.7 11 1.70 0.94–3.08 16.5
Nose 3 3.43 1.10–10.67 11.7 0 — — —
Breast 83 1.23 0.98–1.54 99.4 67 1.38 1.08–1.75 58.9
Bladder 37 1.46 1.05–2.04 60.1 11 1.15 0.64–2.08 16.2
Non-epithelial
Thyroid gland 5 2.82 1.17–6.48 29.9 1 1.20 0.17–8.50 8.3
Connective tissue 5 3.69 1.52–8.94 23.2 1 1.81 0.25–12.84 7.7
Non-Hodgkin lymphoma 6 0.90 0.40–2.02 61.7 7 2.72 1.30–5.71 12.3
CUP 14 2.25 1.31–3.86 56.0 3 1.66 0.54–5.15 10.6
Table 4. Familial associations of histology-specific ovarian cancer with other cancers. CUP: cancer of unknown 
primary. Bolding, italic and underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 
1.00 respectively. aall cancers include ovarian cancers and all other cancers. ball cancers include all other cancers 
except ovarian cancer.
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cancer, which suggests these two cancers share common risk factors. Furthermore, breast cancer was associated 
with many histological types of epithelial ovarian cancers (endometrioid, serous and mucinous) with homoge-
nous RRs between 1.20–1.40; this may suggest that different epithelial ovarian cancers share the similar risks with 
breast cancer. Smoking is a risk factor of mucinous ovarian cancer and, accordingly, the associated cancers were 
mostly smoking-related, including cancers in upper aerodigestive tract, nose, breast, bladder and gallbladder3. 
The most consistent association of lung cancer was found with undifferentiated ovarian cancer.
Ovarian cancer was associated with liver cancer in the two-way comparison (joint P < 2.5 × 10−5). As liver 
cancer in the 7th revision of International Classification of Diseases (ICD-7) encompasses cancers in primary 
liver, gallbladder, extrahepatic bile ducts and ampulla of vater, we performed subtype analyses for liver cancer. 
The only significant association was with gallbladder cancer, and notably, with mucinous ovarian cancers in the 
two-way comparison. Some common risk factors, such as smoking and obesity, may contribute to the association 
between ovarian cancer and gallbladder cancer3,27,28.
We found some curious associations with rare cancers most notably with cancer of the nose, which showed a 
two-way association with endometrioid ovarian cancer and a one-way association with mucinous ovarian cancer. 
Some known risk factors for  cancer of the nose, such as smoking and wood dust exposure, are an unlikely expla-
nation for this finding29. However, Epstein-Barr virus infection, particularly in transiently immunocompromised 
individuals, has been associated with cancer of the nose and this may be a plausible explanation for the present 
findings30,31. The other rare cancers associating with ovarian cancer were male and female genital cancers; the 
common denominator for which is squamous cell histology and human papilloma virus infection etiology30,32,33. 
An increased risk of Hodgkin lymphoma, another Epstein-Barr virus related cancer, was observed in two families 
for each with two or more patients with ovarian cancer30. A note of caution is warranted as the number of cases 
with family history was small and this number of virally related cancers can be associated with ovarian cancer by 
chance. Nevertheless, this is an interesting finding and can be a guidance for further study. Some possible mech-
anisms could be socioeconomic factors and pro-inflammatory effects of obesity34.
CUP is a fatal cancer which is diagnosed at a metastatic stage and no primary site can be found. Familial asso-
ciation of CUP with many primary cancers, including ovarian cancer, was reported previously35. In that report 
we hypothesized that the primary cancers in family members of CUP patients would indicate the location of the 
primary cancer from which CUP was originating. In the present study, ovarian cancer was associated with CUP 
in the two-way comparison (joint P < 2.5 × 10−6); the previous hypothesis predicted that the primary site for CUP 
may be the ovary.
Non-epithelial malignancies of the ovary account for around 10% of all ovarian cancers in our database and 
the risk factors and genetic characteristics of non-epithelial ovarian cancer are poorly understood2. In our study, 
non-epithelial ovarian cancers were associated with thyroid gland and connective tissue cancers, non-Hodgkin 
lymphoma and CUP, but the associations were based on a single significant RR each.
The main limitation of this study is that the patients with identifiable histology were diagnosed only after 1993 
since the introduction of ICD-O/2 in the cancer registry. This affects familial risk estimates because 22 years of 
follow-up is short for intergenerational studies considering risks of both the parental and offspring generations. 
Furthermore, histological classification has not been updated to meet the current guidelines. For example, serous 
histology is now considered to be either low-grade or high-grade with different prognoses and molecular events/
etiologies. Although, to the best of our knowledge, this study on familial associations between ovarian cancer 
with other cancers had the largest sample size ever reported, the data lack sufficient power in many comparisons. 
As indicated in the tables, only a few associations had 80% or higher power to detect significant results. This 
also limits use of techniques such as the Bonferroni correction in adjustments for multiple testing, as has been 
discussed36. Insufficient clinico-behavioral information, such as smoking, is also a caveat in the analysis since 
they can be construed as potential confounders. However, as we adjusted the data for socioeconomic factors, this 
Histology Cancer site
Risk of ovarian cancer Risk of other cancer
N RR 95% CI
Power (%) 




All cancersa 134 1.45 1.07–1.97 37.3 119 1.23 1.03–1.48 82.6
All cancersb 116 1.29 0.94–1.77 36.9 110 1.16 0.96–1.40 81.9
Clear cell
All cancersa 302 0.99 0.82–1.18 84.8 168 1.01 0.87–1.18 96.2
All cancersb 287 0.96 0.80–1.15 84.2 161 0.99 0.85–1.16 95.9
Endometrioid
All cancersa 675 1.41 1.23–1.61 95.7 477 1.21 1.11–1.32 100.0
All cancersb 627 1.34 1.17–1.54 95.4 448 1.16 1.06–1.27 100.0
Serous
All cancersa 2663 1.19 1.12–1.27 100.0 1781 1.04 1.00–1.09 100.0
All cancersb 2448 1.13 1.04–1.23 100.0 1711 1.02 0.98–1.07 100.0
Mucinous
All cancersa 439 1.19 1.02–1.38 93.6 290 1.05 0.94–1.18 99.9
All cancersb 421 1.17 1.00–1.37 93.2 278 1.03 0.91–1.16 99.9
Non-epithelial
All cancersa 159 1.00 0.79–1.27 69.6 80 1.03 0.83–1.28 88.8
All cancersb 154 1.00 0.79–1.27 68.9 76 1.00 0.80–1.25 88.2
Table 5. Familial associations of histology-specific ovarian cancer with any cancer. Bolding, italic and 
underlining indicate that the 95% CI, 99% CI and 99.9% CI did not overlap with 1.00 respectively. aall cancers 
include ovarian cancers and all other cancers. ball cancers include all other cancers except ovarian cancer.
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reduces greatly the possible confounding by smoking37. We have no genetic information for the ovarian cancer 
patients and the explanation for associations between cancers are based on speculation, which should be consid-
ered with caution.
In summary, discordant cancers were by far more common (61.2%) in ovarian cancer families than multiple 
ovarian cancers (4.5%). We found that ovarian cancer was associated with a group of discordant cancers, among 
which colorectal, breast, endometrial and liver cancers and CUP were significant in the two-way analysis. Some 
cancers were only associated with specific histological types of ovarian cancers; for example endometrial cancer 
was only significant with endometrioid types, and breast cancer was associated with endometrioid, serous and 
mucinous with homogenous familial risks. The novel associations with cancer of nose and that of male and female 
genitals were noted but the common etiological mechanism remains to be established. Our results should have 
implications for genetic counseling, and they may provide clues about shared genetic and/or environmental risk 
factors of ovarian cancer with other cancers.
Methods
The Swedish Family-Cancer Database is the combination of the Multigeneration Register, national Cancer 
Registry (started in 1958), national censuses and Cause of Death Register. It includes all Swedish residents born 
after 1931 (offspring generation) and their biological parents (parental generation). The latest version of the 
Swedish Family-Cancer Database contains 16.1 million individuals among which almost 2.0 million were cancer 
patients recorded to the end of 2015.
Most common primary cancers (35) and CUP were identified with the 3-digital codes of ICD-7. According to 
SNOMED codes which were available in the database since 1993, “80203” was classified as undifferentiated ovar-
ian cancer, “83103” as clear cell, “83803” as endometrioid, “84413” and “84603” as serous, “84703” as mucinous, 
and “86203” as thecoma. Thecoma was used to represent non-epithelial ovarian cancer. The follow-up for cancer 
in offspring generation commenced from the beginning of 1958 (for histological analysis it was the beginning 
of 1993), the birth year, or the immigration year, whichever came latest. The follow-up was terminated when a 
person was diagnosed with cancer, emigrated or died, or at the end of 2015, whichever came first.
All patients had a complete family history (including both parents) and cancer data with full diagnostic 
detailed collected by the Cancer Registry. The number of first-degree relatives (parents and/or siblings) who were 
affected with cancer was considered as the family history. Relative risks (RRs), calculated for the offspring gen-
eration, were used as a measure of assessing familial risks by comparing incidence rates for persons with affected 
relatives to incidence rates for those whose relatives had no cancer. In the two-way comparison (Fig. 1), firstly, 
RR for ovarian cancer (or specific histological ovarian cancer) was calculated when family history was discordant 
cancer X, and then in the reverse order RR for cancer X was calculated when family history was ovarian cancer 
(or specific histological ovarian cancer). For parents and offspring (large majority of familial cases) these compar-
isons are independent but for siblings the pairs of cases are the same. Significant results in two-way analyses pro-
vide support for a true association but a lacking two-way association is not strong evidence against an association 
because age distributions and case numbers may differ between two-way analyses.
Poisson regression model was employed to estimate RRs and corresponding confidence intervals (CI) at 5%, 
1% and 0.1% significance levels. These can be combined to calculate a joint significance for non-dependent asso-
ciations; for example if the significant levels of two independent associations are 0.05 and 0.01, the joint signifi-
cance is 0.000538. Studies with multiple testing require statistical approaches to distinguish likely true associations 
from chance findings resulting from multiple tests, as has been described earlier39. In our study, we use different 
significance levels and joint p-values in order to differentiate the likely true associations from likely chance find-
ings. We want to point out that the joint significance is used as a guidance for a Bonferroni-type adjustment as 
hundreds of comparisons were done. A single 95%CI is not very informative in the context of multiple compar-
isons. Statistical power was calculated to detect a significant association for two-sided 95% confidence level with 
an RR of 1.20 for one affected first-degree relative and an RR of 1.40 for at least two affected first-degree relatives. 
In the power calculation for bladder cancer and histology subtype analysis, the RR was set as 1.4. Trend tests 
were performed by modeling the number of first-degree relatives affected by cancer X as a continuous covariate. 
Potential confounders, including age group (17 groups with 5-year gap), sex, calendar period, residential area and 
socioeconomic status as well as parity for ovarian cancer risk, were added to the model as covariates. SAS version 
9.4 was used to perform the statistical analysis.
Ethical Statement. The study was approved by the Ethical Committee of Lund University without require-
ment for informed consent, and the study was conducted in accordance with the approved guidelines.
Data Availability Statement. The data that support the findings of this study are available from Lund 
University but restrictions apply to the availability of these data, which were used under license for the current 
study and so are not publicly available.
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